Literature DB >> 19656187

Regulation of cathepsin B activity by 2A2 monoclonal antibody.

Bojana Mirković1, Ales Premzl, Vesna Hodnik, Bojan Doljak, Zala Jevnikar, Gregor Anderluh, Janko Kos.   

Abstract

Cathepsin B (EC 3.4.22.1) is a lysosomal cysteine protease with both endopeptidase and exopeptidase activity. The former is associated with the degradation of the extracellular matrix proteins, which is a process required for tumour cell invasion and metastasis. In the present study, we show that 2A2 monoclonal antibody, raised by our group, is able to regulate cathepsin B activity. The EPGYSP sequence, located between amino acid residues 133-138 of cathepsin B in the proximity of the occluding loop, was determined to be the epitope for 2A2 monoclonal antibody using SPOT analysis. By surface plasmon resonance, an equilibrium dissociation constant (Kd) of 4.7 nM was determined for the interaction between the nonapeptide CIAEPGYSP, containing the epitope sequence, and 2A2 monoclonal antibody. 2A2 monoclonal antibody potentiated cathepsin B exopeptidase activity with a activation constant (Ka) of 22.3 nM, although simultaneously inhibiting its endopeptidase activity. The median inhibitory concentration values for the inhibition of hydrolysis of protein substrates, BODIPY FL casein and DQ-collagen IV were 761 and 702 nM, respectively. As observed by native gel electrophoresis and gel filtration, the binding of 2A2 monoclonal antibody to the cathepsin B/cystatin C complex caused the dissociation of cystatin C from the complex. The results obtained in the present study suggest that, upon binding, the 2A2 monoclonal antibody induces a conformational change in cathepsin B, stabilizing its exopeptidase conformation and thus disabling its harmful action associated with its endopeptidase activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656187     DOI: 10.1111/j.1742-4658.2009.07171.x

Source DB:  PubMed          Journal:  FEBS J        ISSN: 1742-464X            Impact factor:   5.542


  5 in total

1.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

2.  Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity.

Authors:  Bojana Mirković; Boštjan Markelc; Miha Butinar; Ana Mitrović; Izidor Sosič; Stanislav Gobec; Olga Vasiljeva; Boris Turk; Maja Čemažar; Gregor Serša; Janko Kos
Journal:  Oncotarget       Date:  2015-08-07

3.  New Kid on the Block.

Authors:  Thomas Reinheckel
Journal:  Theranostics       Date:  2017-07-30       Impact factor: 11.556

4.  Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in significantly improved anti-tumor activity in vitro and in vivo.

Authors:  Ana Mitrović; Izidor Sosič; Špela Kos; Urša Lampreht Tratar; Barbara Breznik; Simona Kranjc; Bojana Mirković; Stanislav Gobec; Tamara Lah; Gregor Serša; Janko Kos
Journal:  Oncotarget       Date:  2017-07-17

5.  Cystatin C and lactoferrin concentrations in biological fluids as possible prognostic factors in eye tumor development.

Authors:  Mariya A Dikovskaya; Alexandr N Trunov; Valeriy V Chernykh; Tatyana A Korolenko
Journal:  Int J Circumpolar Health       Date:  2013-08-05       Impact factor: 1.228

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.